Comprehensive clinical development programs being initiated for each investigational candidate
Innovent will supply sintilimab for the collaborated clinical trial
Elpiscience will receive up to US $37 million, including the upfront payment and license option fees
If approved, patritumab deruxtecan would be a first-in-class HER3 directed DXd antibody drug conjugate for these patients
The commissioning of the facility represents the culmination of a £45m investment to address rapidly growing demand for ADC manufacturing, supported by a £2.4m Scottish Enterprise grant
Conditional marketing authorization is based on clinically meaningful response rates, duration of response, and safety from the Phase 2 MagnetisMM-3 trial
Biologics manufacturing to expand the Aragen platform by offering “gene to GMP” solution
The companies plan to start a pivotal Phase 3 trial in the coming months
Approval based on DESTINY-Lung02 results where AstraZeneca and Daiichi Sankyo’s Enhertu demonstrated a confirmed objective response rate of 49% and median duration of response of 16.8 months in previously treated patients
Merck to pay Daiichi Sankyo a $4 billion upfront payment in addition to $1.5 billion in continuation payments over the next 24 months
Subscribe To Our Newsletter & Stay Updated
